Sungwon Lim founded ImpriMed on the 4 of may of 2017 (may the 4th be with you) with a strong motivation to innovate a way to help cancer patients who need an effective treatment ‘today’, by optimizing and personalizing drug treatment options that are currently available and they help veterinary oncologists to screen the most effective treatment options with 82% prediction accuracy and exclude out non-effective ones with 80% accuracy and now they are providing their service to dogs with cancer with a focus to expand into cats in the near future, so far, they’ve served 750 dog cancer cases (500 patients in a half year), their service is available for 99 veterinary oncologists at 77 vet hospitals in 26 different states in the US and continuously expanding the client network and service coverage area and successfully raised $4M Seed round from prestigious Silicon Valley VCs and international VCs, and just started to raise our Series A to fast scale up our business to the entire US pet cancer market and also open the Japan market.
(Be sure to watch the video interview below!)
Sungwon Lim has a PhD in Bioengineering at Stanford University, a MS in Translational Medicine at UC Berkeley & UC San Francisco in a join Bioengineering program, a BS in Chemical Engineering at KAIST (Korea Advanced Institute of Science and Technology) and has 12 years of academic research experiences in pharmaceutical and biotech companies.
Interview with Sungwon Lim:
(Click the play button to watch the video interview above)
Click here to watch in a new Tab: https://www.youtube.com/watch?v=DXexR0Yb09s